Have a feature idea you'd love to see implemented?
Let us know!
ENTX Entera Bio Ltd
Price (delayed)
$1.62
Market cap
$59.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$53.06M
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due
Highlights
Entera Bio's revenue has soared by 74% from the previous quarter
Entera Bio's gross profit has soared by 50% YoY
ENTX's quick ratio has surged by 67% year-on-year but it is down by 11% since the previous quarter
The equity has declined by 24% since the previous quarter but it has increased by 3.5% year-on-year
ENTX's gross margin has dropped by 79% year-on-year and by 42% since the previous quarter
Key stats
What are the main financial stats of ENTX
Market
Valuations
Earnings
Shares outstanding
36.83M
Market cap
$59.67M
Enterprise value
$53.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
9.12
Price to sales (P/S)
616
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
535.98
Revenue
$99,000
EBIT
-$9.18M
EBITDA
-$9.13M
Free cash flow
-$7.97M
Per share
Balance sheet
Liquidity
EPS
-$0.26
Free cash flow per share
-$0.21
Book value per share
$0.18
Revenue per share
$0
TBVPS
$0.21
Total assets
$7.74M
Total liabilities
$1.29M
Debt
$309,000
Equity
$6.45M
Working capital
$6.23M
Debt to equity
0.05
Current ratio
6.61
Quick ratio
6.26
Net debt/EBITDA
0.72
Margins
Efficiency
Dividend
EBITDA margin
-9,222.2%
Gross margin
9.1%
Net margin
-9,270.7%
Operating margin
-9,314.1%
Return on assets
-92.3%
Return on equity
-107.2%
Return on invested capital
-9,317.8%
Return on capital employed
-138.4%
Return on sales
-9,270.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENTX stock price
How has the Entera Bio stock price performed over time
Intraday
4.52%
1 week
-8.99%
1 month
-12.43%
1 year
121.92%
YTD
170%
QTD
-14.74%
Financial performance
How have Entera Bio's revenue and profit performed over time
Revenue
$99,000
Gross profit
$9,000
Operating income
-$9.22M
Net income
-$9.18M
Gross margin
9.1%
Net margin
-9,270.7%
ENTX's operating margin has surged by 87% year-on-year and by 38% since the previous quarter
The net margin has surged by 87% year-on-year and by 38% since the previous quarter
ENTX's gross margin has dropped by 79% year-on-year and by 42% since the previous quarter
Entera Bio's revenue has soared by 74% from the previous quarter
Growth
What is Entera Bio's growth rate over time
Valuation
What is Entera Bio stock price valuation
P/E
N/A
P/B
9.12
P/S
616
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
535.98
The EPS is up by 24% year-on-year
ENTX's P/B is 103% above its 5-year quarterly average of 4.5 and 36% above its last 4 quarters average of 6.7
The equity has declined by 24% since the previous quarter but it has increased by 3.5% year-on-year
Entera Bio's revenue has soared by 74% from the previous quarter
The stock's price to sales (P/S) is 62% more than its 5-year quarterly average of 381.3
Efficiency
How efficient is Entera Bio business performance
The return on sales has surged by 87% year-on-year and by 38% since the previous quarter
Entera Bio's ROA has decreased by 10% from the previous quarter
ENTX's return on equity is down by 7% since the previous quarter but it is up by 2% year-on-year
Dividends
What is ENTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENTX.
Financial health
How did Entera Bio financials performed over time
The current ratio has surged by 67% year-on-year but it has declined by 11% since the previous quarter
ENTX's quick ratio has surged by 67% year-on-year but it is down by 11% since the previous quarter
The debt is 95% smaller than the equity
Entera Bio's debt to equity has increased by 25% from the previous quarter but it has decreased by 17% YoY
The equity has declined by 24% since the previous quarter but it has increased by 3.5% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.